Jump to navigation Jump to search
Tofisopam Wiki Str.png
Tofisopam 3D.png
Clinical data
  • ?
Routes of
ATC code
Legal status
Legal status
  • ?
Pharmacokinetic data
Elimination half-life6-8 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass382.5

WikiDoc Resources for Tofisopam


Most recent articles on Tofisopam

Most cited articles on Tofisopam

Review articles on Tofisopam

Articles on Tofisopam in N Eng J Med, Lancet, BMJ


Powerpoint slides on Tofisopam

Images of Tofisopam

Photos of Tofisopam

Podcasts & MP3s on Tofisopam

Videos on Tofisopam

Evidence Based Medicine

Cochrane Collaboration on Tofisopam

Bandolier on Tofisopam

TRIP on Tofisopam

Clinical Trials

Ongoing Trials on Tofisopam at Clinical

Trial results on Tofisopam

Clinical Trials on Tofisopam at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Tofisopam

NICE Guidance on Tofisopam


FDA on Tofisopam

CDC on Tofisopam


Books on Tofisopam


Tofisopam in the news

Be alerted to news on Tofisopam

News trends on Tofisopam


Blogs on Tofisopam


Definitions of Tofisopam

Patient Resources / Community

Patient resources on Tofisopam

Discussion groups on Tofisopam

Patient Handouts on Tofisopam

Directions to Hospitals Treating Tofisopam

Risk calculators and risk factors for Tofisopam

Healthcare Provider Resources

Symptoms of Tofisopam

Causes & Risk Factors for Tofisopam

Diagnostic studies for Tofisopam

Treatment of Tofisopam

Continuing Medical Education (CME)

CME Programs on Tofisopam


Tofisopam en Espanol

Tofisopam en Francais


Tofisopam in the Marketplace

Patents on Tofisopam

Experimental / Informatics

List of terms related to Tofisopam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Tofisopam (marketed under brand names Emandaxin and Grandaxin) is a drug which is a benzodiazepine derivative. Like other benzodiazepines, it possesses anxiolytic properties but unlike other benzodiazepines it does not have anticonvulsant, sedative,[1] skeletal muscle relaxant, motor skill-impairing or amnestic[2] properties. While it may not be an anticonvulsant in and of itself, it has been shown to enhance the anticonvulsant action of classical 1,4-benzodiazepines such as diazepam (but not sodium valproate, carbamazepine, phenobarbital, or phenytoin).[3] Tofisopam is indicated for the treatment of anxiety and alcohol withdrawal, and is prescribed in a dosage of 50 - 300mg per day divided into three doses. Peak plasma levels are attained two hours after an oral dose. Tofisopam is not reported as causing dependance to the same extent as other benzodiazepines, but is still recommended to be prescribed for a maximum of 12 weeks. [4]

Tofisopam is not approved for sale in the United States or Canada. However, Vela Pharmaceuticals of New Jersey is developing the D- enantiomer (dextofisopam) as a treatment for irritable bowel syndrome.[5]


  1. Bond, A (1982). "A comparison of the psychotropic profiles of tofisopam and diazepam". European Journal of Clinical Pharmacology. 22 (2): 137–42. PMID 6124424. Unknown parameter |coauthors= ignored (help)
  2. Seppala, T (1980). "Tofisopam, a novel 3,4-benzodiazepine: multiple-dose effects on psychomotor skills and memory. Comparison with diazepam and interactions with ethanol". Psychopharmacology (Berlin). 69 (2): 209–18. PMID 6109345. Unknown parameter |coauthors= ignored (help)
  3. Saano, V. (1986). "Tofizopam selectively increases the action of anticonvulsants". Medical Biology. 64 (4): 201–6. PMID 3023768.
  5. Vela Pharmaceuticals (2005). "Vela Announces Positive Phase 2 Results for Dextofisopam in Treating Irritable Bowel Syndrome - IBS: Results Show Effects of Dextofisopam Both in Women and in Men". VelaPharm - News. Retrieved 21 February. Unknown parameter |accessyear= ignored (|access-date= suggested) (help); Check date values in: |accessdate= (help)

External links

Template:Benzodiazepines Template:Anxiolytics

Template:Pharma-stub Template:WikiDoc Sources